LIPOSORBER LA-15 SYSTEM

Lipoprotein, Low Density, Removal

FDA Premarket Approval P910018 S005

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Approval for 1) replacing the sterilization date with the actual expiration date, expressed as month and year, for the liposorber(r) la-15 system components: liposorber(r) la-15 column, sulflux(r) fs-05 plasma separator, and the tubing sytem for plasmapheresis lt-ma2; 2) replacing the slip-type male tubing connectors with luer-lock type connectors on the separator end-caps of te sulflux fs-05 plasma separator; 3) making the following changes to the tubing system for the plasmapheresis lt-ma2: a) providing sterile transducer protective filters (found substantially equivalent under 510(k) k983076) in packages of ten; b) reducing the number of connection tubes from ten to eight, adding pinch clips and reducing the sharpness of the plastic spike on each end of the connection tube; c) replacing the stainless steel needles, used to connect each infusion line to a bag or bottle of saline or regeneration fluid, with plastic spikes; d) adding a luer-lock "male" and "female" connector to the end of the waste lines; e) increasing the length of the tubing section between the blood pump and chanber level 1 from 80 mm to 90 mm and the length of the tubing section between the waste drip chamber and a "t" dconnector on the waste line from 35 m to 50 mm; and f) adding an infusion line.

DeviceLIPOSORBER LA-15 SYSTEM
Classification NameLipoprotein, Low Density, Removal
Generic NameLipoprotein, Low Density, Removal
ApplicantKANEKA PHARMA AMERICA CORP.
Date Received2000-06-20
Decision Date2000-12-06
PMAP910018
SupplementS005
Product CodeMMY
Advisory CommitteeGastroenterology/Urology
Supplement TypeNormal 180 Day Track
Supplement ReasonChange Design/components/specifications/material
Expedited ReviewNo
Combination Product No
Applicant Address KANEKA PHARMA AMERICA CORP. 546 Fifth Ave., 21st Floor new York, NY 10036

Supplemental Filings

Supplement NumberDateSupplement Type
P910018Original Filing
S034 2022-05-31 30-day Notice
S033 2022-03-30 30-day Notice
S032 2021-12-17 Special (immediate Track)
S031 2021-06-28 30-day Notice
S030 2021-03-31 30-day Notice
S029
S028 2020-11-27 30-day Notice
S027 2019-08-13 Normal 180 Day Track
S026 2019-04-23 30-day Notice
S025 2018-03-29 30-day Notice
S024 2018-03-01 30-day Notice
S023 2018-02-16 Normal 180 Day Track
S022 2017-03-31 Normal 180 Day Track
S021 2016-07-29 Normal 180 Day Track
S020 2016-04-20 Normal 180 Day Track
S019 2016-04-08 30-day Notice
S018 2016-02-16 30-day Notice
S017 2015-04-10 Normal 180 Day Track
S016 2012-05-21 30-day Notice
S015 2011-11-08 Normal 180 Day Track
S014
S013 2009-10-27 Normal 180 Day Track No User Fee
S012 2006-09-08 Normal 180 Day Track
S011 2006-04-20 Normal 180 Day Track
S010
S009 2003-01-15 30-day Notice
S008
S007 2000-08-22 Normal 180 Day Track
S006 2000-08-07 30-day Notice
S005 2000-06-20 Normal 180 Day Track
S004
S003
S002 1998-12-15 Normal 180 Day Track
S001 1998-11-02 Normal 180 Day Track

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.